VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion

Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.

Alexis Borisy Relay Therapeutics
Relay Executive Chairman and Interim CEO Alexis Borisy • Source: Relay Therapeutics

Relay Therapeutics has launched with $57m in Series A venture capital to identify new drug targets and to find new ways of addressing difficult targets by studying proteins in motion rather than looking at static images.

“If a picture is worth a thousand words, a video is worth a thousand pictures,” Relay’s Executive Chairman and Interim...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip